AMPH vs. KROS, MRVI, DCPH, RCKT, NAMS, RNA, TGTX, GERN, VERA, and GLPG
Should you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Keros Therapeutics (KROS), Maravai LifeSciences (MRVI), Deciphera Pharmaceuticals (DCPH), Rocket Pharmaceuticals (RCKT), NewAmsterdam Pharma (NAMS), Avidity Biosciences (RNA), TG Therapeutics (TGTX), Geron (GERN), Vera Therapeutics (VERA), and Galapagos (GLPG). These companies are all part of the "pharmaceutical preparations" industry.
Amphastar Pharmaceuticals (NASDAQ:AMPH) and Keros Therapeutics (NASDAQ:KROS) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends, profitability and community ranking.
65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 22.9% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Amphastar Pharmaceuticals received 346 more outperform votes than Keros Therapeutics when rated by MarketBeat users. Likewise, 66.84% of users gave Amphastar Pharmaceuticals an outperform vote while only 66.10% of users gave Keros Therapeutics an outperform vote.
Amphastar Pharmaceuticals has higher revenue and earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amphastar Pharmaceuticals has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
Amphastar Pharmaceuticals has a net margin of 21.34% compared to Keros Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.95% beat Keros Therapeutics' return on equity.
In the previous week, Amphastar Pharmaceuticals had 7 more articles in the media than Keros Therapeutics. MarketBeat recorded 9 mentions for Amphastar Pharmaceuticals and 2 mentions for Keros Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.35 beat Keros Therapeutics' score of 0.30 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.
Amphastar Pharmaceuticals currently has a consensus target price of $66.00, indicating a potential upside of 54.82%. Keros Therapeutics has a consensus target price of $86.00, indicating a potential upside of 42.43%. Given Amphastar Pharmaceuticals' higher probable upside, equities analysts clearly believe Amphastar Pharmaceuticals is more favorable than Keros Therapeutics.
Summary
Amphastar Pharmaceuticals beats Keros Therapeutics on 13 of the 18 factors compared between the two stocks.
Get Amphastar Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amphastar Pharmaceuticals Competitors List
Related Companies and Tools
